PANEL DISCUSSION: Lessons Learned from Failed and Discontinued Clinical Trials for the Treatment of Glioblastoma
Time: 5:15 pm
day: Day Two
Details:
- Debate the common challenges with moving GBM clinical trials forward
- What can we learn from the plethora of failed phase 2 trials?
- With a high failure rate of phase 3 glioblastoma trials, panellists examine the need for greater reliability
of earlier studies
Speakers:
Dr. Skolnik oversees all of Inovio’s cancer immunotherapy programs, as well as those for several infectious diseases. Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He was also a Medical Affairs lead…Read more
